<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03394781</url>
  </required_header>
  <id_info>
    <org_study_id>C928-008</org_study_id>
    <nct_id>NCT03394781</nct_id>
  </id_info>
  <brief_title>A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)</brief_title>
  <official_title>A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Durect</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research trial testing DUR-928 (an experimental medication). The purpose of the&#xD;
      trial is to assess whether treatment with DUR-928 has any effect on the treatment of Primary&#xD;
      Sclerosing Cholangitis (PSC). This trial will also assess safety (side effects).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">January 22, 2018</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>through 4 weeks of dosing until 56 days post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change of ALP from baseline</measure>
    <time_frame>through 4 weeks of dosing until 56 days post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change of liver enzymes</measure>
    <time_frame>through 4 weeks of dosing until 56 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change of selected biomarkers</measure>
    <time_frame>through 4 weeks of dosing until 56 days post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>DUR-928 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg oral suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DUR-928 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg oral suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DUR-928</intervention_name>
    <description>oral suspension daily for 28 days</description>
    <arm_group_label>DUR-928 10 mg</arm_group_label>
    <arm_group_label>DUR-928 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Verified diagnosis of PSC for at least 12 months, with or without IBD.&#xD;
&#xD;
          -  Serum (ALP) â‰¥ 1.5 times ULN and with no &gt;15% fluctuation in the past 3 months.&#xD;
&#xD;
          -  In subjects receiving treatment with ursodeoxycholic acid (UDCA), therapy must be&#xD;
             stable for at least 3 months and at a dose not greater than 20 mg/kg/day.&#xD;
&#xD;
          -  Subjects of childbearing potential must agree to use a medically acceptable method of&#xD;
             contraceptive to prevent pregnancy in the subject and/or the partner for the duration&#xD;
             of their participation in the trial up to 2 months after the last study drug dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of documented secondary sclerosing cholangitis or small duct PSC&#xD;
&#xD;
          -  Bacterial cholangitis within 30 days prior to Screening&#xD;
&#xD;
          -  Presence of percutaneous drain or endoscopic bile duct stent&#xD;
&#xD;
          -  History of, or suspicion of cholangiocarcinoma.&#xD;
&#xD;
          -  Prior liver transplantation, or currently listed for liver transplantation&#xD;
&#xD;
          -  Presence of other concomitant liver diseases&#xD;
&#xD;
          -  Moderate to Severe active IBD or flare in colitis activity within the last 3 months&#xD;
&#xD;
          -  Any severe and/or untreated concomitant cardiovascular, renal, endocrine or&#xD;
             psychiatric disorder&#xD;
&#xD;
          -  Any active malignant disease (within 3 years), other than non-melanomatous skin cancer&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Existing or intended pregnancy, or breast feeding&#xD;
&#xD;
          -  Has received medication from another clinical trial within the past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alastair Smith, MD</last_name>
    <role>Study Director</role>
    <affiliation>INC Research/InVentiv Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Therapy and Advanced Research</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Mecklenburg Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <disposition_first_submitted>August 14, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 14, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 20, 2020</disposition_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

